Literature DB >> 17420384

Acetazolamide in the treatment of X-linked retinoschisis maculopathy.

Mehdi Ghajarnia, Michael B Gorin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17420384     DOI： 10.1001/archopht.125.4.571

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  21 in total

1.  Acetazolamide for cystoid macular oedema in Bietti crystalline retinal dystrophy.

Authors:  Geoffrey K Broadhead; Andrew A Chang
Journal:  Korean J Ophthalmol       Date:  2014-03-14

2.  R102W mutation in the RS1 gene responsible for retinoschisis and recurrent glaucoma.

Authors:  Xiu-Feng Huang; Chang-Sen Tu; Dong-Jun Xing; De-Kang Gan; Ge-Zhi Xu; Zi-Bing Jin
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

Review 3.  X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms.

Authors:  Robert S Molday; Ulrich Kellner; Bernhard H F Weber
Journal:  Prog Retin Eye Res       Date:  2012-01-03       Impact factor: 21.198

4.  Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin.

Authors:  Guo-Jie Ye; Ewa Budzynski; Peter Sonnentag; Paul E Miller; Alok K Sharma; James N Ver Hoeve; Kellie Howard; David R Knop; Martha Neuringer; Trevor McGill; Jonathan Stoddard; Jeffrey D Chulay
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09       Impact factor: 5.032

5.  Abnormal cone structure in foveal schisis cavities in X-linked retinoschisis from mutations in exon 6 of the RS1 gene.

Authors:  Jacque L Duncan; Kavitha Ratnam; David G Birch; Sanna M Sundquist; Anna S Lucero; Yuhua Zhang; Meira Meltzer; Nizar Smaoui; Austin Roorda
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-20       Impact factor: 4.799

Review 6.  Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis.

Authors:  Ronald A Bush; Lisa L Wei; Paul A Sieving
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-22       Impact factor: 6.915

7.  Efficacy of topical dorzolamide for treatment of cystic macular lesions in a patient with enhanced S-cone syndrome.

Authors:  Mohamed A Genead; Gerald A Fishman; J Jason McAnany
Journal:  Doc Ophthalmol       Date:  2010-09-15       Impact factor: 2.379

8.  Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits.

Authors:  Dario Marangoni; Zhijian Wu; Henry E Wiley; Caroline J Zeiss; Camasamudram Vijayasarathy; Yong Zeng; Suja Hiriyanna; Ronald A Bush; Lisa L Wei; Peter Colosi; Paul A Sieving
Journal:  Hum Gene Ther Clin Dev       Date:  2014-12       Impact factor: 5.032

9.  Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide.

Authors:  Alessandro Iannaccone; Kenneth H Fung; Mari E Eyestone; Edwin M Stone
Journal:  Am J Ophthalmol       Date:  2008-10-04       Impact factor: 5.258

10.  Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin.

Authors:  Saloni Walia; Gerald A Fishman; Robert S Molday; Frank M Dyka; Nalin M Kumar; Mary A Ehlinger; Edwin M Stone
Journal:  Am J Ophthalmol       Date:  2008-10-02       Impact factor: 5.258
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.